Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 601–700 of 1,000
Papadopoulou, L. C., & Tsiftsoglou, A. S. (2013) · Pharmaceuticals · doi:10.3390/ph6010032 · Cited by 21
“achieve blood transfusion independence for four years now in a patient with severe beta thalassemia, being dependent since early childhood on monthly transfusions [54,61].”
BackgroundEverson, E. M., Olzsko, M. E., Leap, D. J., Hocum, J. D., & Trobridge, G. D. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.48 · Cited by 22
Gene Therapy as a Curative Option for β-Thalassemia
Biffi, A. (2018) · New England Journal of Medicine · doi:10.1056/nejme1802169 · Cited by 20
HIV proviral DNA integration can drive T cell growth ex vivo
Yoon, J. K., Holloway, J. R., Wells, D., Kaku, M., Jetton, D., Brown, R. E., & Coffin, J. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013194117 · Cited by 19
Barazesh, M., Mohammadi, S., Bahrami, Y., Mokarram, P., Morowvat, M. H., Saidijam, M., Karimipoor, M., Kavousipour, S., Vosoughi, A. R., & Khanaki, K. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201214115024 · Cited by 18
Gene Editing for Inherited Red Blood Cell Diseases
Bustamante, O. Q., Fañanas-Baquero, S., Dessy-Rodríguez, M., Ojeda-Pérez, I., & Segovia, J. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.848261 · Cited by 20
Integrase deficient lentiviral vector: prospects for safe clinical applications
Yew, C.-H. T., Gurumoorthy, N., Nordin, F., Tye, G. J., Zaman, W. S. W. K., Tan, J. J., & Ng, M. H. (2022) · PeerJ · doi:10.7717/peerj.13704 · Cited by 21
Viral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 24
Gene therapy for β-thalassemia: current and future options
Hardouin, G., Miccio, A., & Brusson, M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.12.001 · Cited by 23
Lentivirus Vectors in β-Thalassemia
Payen, E., Colomb, C., Nègre, O., Beuzard, Y., Hehir, K. M., & Leboulch, P. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00006-5 · Cited by 24
“In spite of these repeated phlebotomies, the patient has not required nor received any blood transfusion for now over 3years (39months), this 4years (51months) after transplantation and gene therapy (Cavazzana-Calvo et al., 2010).”
BackgroundSelf-citationKiem, H., Arumugam, P. I., Burtner, C. R., Fox, C. F., Beard, B. C., Dexheimer, P. J., Adair, J. E., & Malik, P. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.55 · Cited by 20
Lim, T., Geisen, C., Hesse, M., Fleischmann, B. K., Zimmermann, K., & Pfeifer, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070543 · Cited by 19
Foamy Virus Vectors for HIV Gene Therapy
Olszko, M. E., & Trobridge, G. D. (2013) · Viruses · doi:10.3390/v5102585 · Cited by 19
“Clonal expansion and leukemia have occurred in gene therapy clinical trials as a result of vector-mediated dysregulation of nearby genes [20–23,51,52].”
BackgroundHigh-throughput screening identifies compounds that enhance lentiviral transduction
Johnston, J. M., Denning, G., Moot, R., Whitehead, D., Shields, J. E., Doux, J. M. L., Doering, C. B., & Spencer, H. T. (2014) · Gene Therapy · doi:10.1038/gt.2014.80 · Cited by 19
Ex Vivo Selection of Transduced Hematopoietic Stem Cells for Gene Therapy of β-Hemoglobinopathies
Bhukhai, K., Dreuzy, E. D., Giorgi, M., Colomb, C., Nègre, O., Denaro, M., Gillet-Legrand, B., Cheuzeville, J., Paulard, A., Trebeden‐Negre, H., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.015 · Cited by 19
Self-citationGene Addition Strategies for β-Thalassemia and Sickle Cell Anemia
Dong, A., & Rivella, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_6 · Cited by 21
Skipper, K. A., Hollensen, A. K., Antoniou, M. N., & Mikkelsen, J. G. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0570-2 · Cited by 20
Epigenetic Control of Haematopoietic Stem Cell Aging and Its Clinical Implications
Choudry, F., & Frontini, M. (2015) · Stem Cells International · doi:10.1155/2016/5797521 · Cited by 21
“[11] M.”
Traeger‐Synodinos, J., Vrettou, C., & Kanavakis, E. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.7 · Cited by 19
Immune modulation by genetic modification of dendritic cells with lentiviral vectors
Liechtenstein, T., Pérez‐Janices, N., Bricogne, C., Lanna, A., Dufait, I., Goyvaerts, C., Laranga, R., Padella, A., Vargas, F. A., Baratchian, M., et al. (2013) · Virus Research · doi:10.1016/j.virusres.2013.05.007 · Cited by 24
Organ targeted prenatal gene therapy—how far are we?
Mehta, V., Abi-Nader, K. N., Waddington, S. N., & David, A. L. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2787 · Cited by 20
Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia
Breda, L., Rivella, S., Zuccato, C., & Gambari, R. (2013) · Expert Review of Hematology · doi:10.1586/ehm.13.24 · Cited by 22
Stem-cell transplantation in children and adults with sickle cell disease: an update
Khoury, R. A., & Abboud, M. R. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.23 · Cited by 23
Johnson, S. N., Wheeler, J. X., Thorpe, R., Collins, M. K., Takeuchi, Y., & Zhao, Y. (2018) · Biologicals · doi:10.1016/j.biologicals.2017.12.005 · Cited by 20
Clinical application of base editing for treating β-thalassaemia
Lai, Y., Liu, R., Wang, L., Ma, X.-K., Li, Y., Yang, G., Shi, L., Guo, Y., Wei, Z., Zhou, X., et al. (2026) · Nature · doi:10.1038/s41586-026-10342-9 · Cited by 22
Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
Saleh, A. H., Rothe, M., Barber, D. L., McKillop, W. M., Fraser, G. A. M., Morel, C. F., Schambach, A., Auray‐Blais, C., West, M. L., Khan, A., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.01.003 · Cited by 18
“Clonal dominance was also observed in a study that used lentiviral b-globin gene transfer to treat human b-thalassaemia, with vector-induced transcriptional activation of HMGA2 and elevated expression of a truncated HMGA2 mRNA that was insensitive to degradation by let-7 microRNAs.(9)”
BackgroundGroth, A. C., Liu, M., Wang, H., Lovelett, E. A., & Emery, D. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076528 · Cited by 18
“Indeed, a smaller 250 bp core from the cHS4 element with suboptimal enhancer-blocking activity not only failed to prevent malignant transformation in a clinical trial, but is thought to have played a role in the transformation event [19].”
Contributions of Gene Marking to Cell and Gene Therapies
Barese, C. N., & Dunbar, C. E. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.237 · Cited by 19
Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies
Antony, J. S., Dewerth, A., Haque, A., Handgretinger, R., & Kormann, M. S. D. (2015) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-015-0022-6 · Cited by 19
Romero, Z. G., Campo-Fernández, B., Wherley, J., Kaufman, M. L., Urbinati, F., Cooper, A. R., Hoban, M. D., Baldwin, K. M., Lumaquin, D., Wang, X., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.12 · Cited by 19
Suwanmanee, T., Ferris, M. T., Hu, P., Gui, T., Montgomery, S. A., de Villena, F. P., & Kafri, T. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.009 · Cited by 18
“Notably, among all HIV-1 vector-treated patients, only one patient who received hematopoietic-stem-celldirected gene replacement therapy of b-thalassemia demonstrated vector-induced insertional mutagenesis.(20) The variability in the efficacy and safety of HIV-based vector clinical trials was in line with earlier prec…”
ResultChitosan-Based Systems for Gene Delivery
Sharma, D., Arora, S., Rodrigues, B. D. S., Lakkadwala, S., Banerjee, A., & Singh, J. (2019) · Springer eBooks · doi:10.1007/978-981-15-0263-7_8 · Cited by 22
Novel therapies in β‐thalassaemia
Grech, L., Borg, K., & Borg, J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14918 · Cited by 19
“5–9 g/dL.(72) Further improvement of the HPV569 β-globin vector, GRECH ET AL.”
BackgroundThe case for intrauterine gene therapy
Mattar, C. N. Z., Waddington, S. N., Biswas, A., Davidoff, A. M., Choolani, M. A., Chan, J. K. Y., & Nathwani, A. C. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.06.006 · Cited by 19
Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide
Taher, A. T., & Cappellini, M. D. (2014) · Drugs · doi:10.1007/s40265-014-0299-0 · Cited by 20
“Interference with (reversal of) developmental fetal hemoglobin silencing corrected the anemia in animal studies [65], while gene therapy has shown similar benefits in human case reports [66].”
Re-engineering an alphoidtetO-HAC-based vector to enable high-throughput analyses of gene function
Kononenko, A. V., Lee, N., Earnshaw, W. C., Kouprina, N., & Larionov, V. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt205 · Cited by 18
Condiotti, R., Goldenberg, D., Giladi, H., Perlman, T. S., Waddington, S. N., Buckley, S. M. K., Heim, D., Cheung, W., Themis, M., Coutelle, C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.193 · Cited by 19
BAY11 enhances OCT4 synthetic mRNA expression in adult human skin cells
Awe, J. P., Crespo, A. V., Li, Y., Kiledjian, M., & Byrne, J. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt163 · Cited by 23
“As these viruses randomly integrate into the genome, insertional mutagenesis is an important safety concern [15-17].”
BackgroundXiao, H., Peng, Y., Yuan, H., Liu, Y., Guo, Z. S., Bartlett, D. L., Fu, N., & He, Y. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101138 · Cited by 18
The case for intrauterine stem cell transplantation
Mattar, C. N. Z., Biswas, A., Choolani, M. A., & Chan, J. K. Y. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.06.005 · Cited by 18
Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy
Browning, D. L., & Trobridge, G. D. (2016) · Biomedicines · doi:10.3390/biomedicines4010004 · Cited by 18
“In this patient, the clone was only dominant in the myeloid restricted lineage and increased gene expression was limited to erythrocytes [49].”
BackgroundPestina, T. I., Hargrove, P. W., Zhao, H., Mead, P. E., Smeltzer, M. P., Weiss, M. J., Wilber, A. C., & Persons, D. A. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.45 · Cited by 19
Labenski, V., Suerth, J. D., Barczak, E., Heckl, D., Lévy, C., Bernadin, O., Charpentier, E., Williams, D. A., Fehse, B., Verhoeyen, E., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.019 · Cited by 18
Wu, L., Xie, J., Tan, L., Mai, Z., Wang, L., Wang, X., & Chen, T. (2017) · Royal Society Open Science · doi:10.1098/rsos.170822 · Cited by 19
Bernaudin, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101523 · Cited by 23
Self-citationAdvances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases
Bueren, J. A., & Auricchio, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.152 · Cited by 17
“…clinical evidence showing significant clinical improvement in a b -thalassemic patient treated by gene therapy was reported by Cavazzana-Calvo et al. 50 A busulfan-conditioned b E / b 0 thalassemic patient was infused with CD34 + cells transduced with an SIN-LV carrying the antisickling b A-T87Q…”
InfluentialStibbs, D. J., Couto, P. S., Takeuchi, Y., Rafiq, Q. A., Jackson, N. B., & Rayat, A. C. M. E. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101209 · Cited by 25
O’Reilly, M., Shipp, A. C., Rosenthal, E. R., Jambou, R., Shih, T., Montgomery, M. O., Gargiulo, L., Patterson, A., & Corrigan‐Curay, J. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00016-8 · Cited by 20
Developments in the treatment of hemophilia B: focus on emerging gene therapy
Gray, J. T., Cancio, M., Reiss, U. M., Nathwani, A. C., & Davidoff, A. M. (2013) · The Application of Clinical Genetics · doi:10.2147/tacg.s31928 · Cited by 19
Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells
Doering, C. B., Archer, D. R., & Spencer, H. T. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.005 · Cited by 18
Estimation of the difference in HbF expression due to loss of the 5' -globin BCL11A binding region
Ghedira, E. S., Lecerf, L., Faubert, E., Costes, B., Moradkhani, K., Bachir, D., Galactéros, F., & Pissard, S. (2012) · Haematologica · doi:10.3324/haematol.2012.061994 · Cited by 17
Interaction of vectors and parental viruses with the host genome
Gil-Fariña, I., & Schmidt, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.004 · Cited by 19
Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis
Biasco, L., Rothe, M., Schott, J. W., & Schambach, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.009 · Cited by 19
Emerging therapies in β-thalassemia: toward a new era in management
Bou‐Fakhredin, R., Tabbikha, R., Daadaa, H., & Taher, A. T. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1752180 · Cited by 20
“in a young male patient with transfusion-dependent β/βthalassemia [48].”
BackgroundCombination of lentiviral and genome editing technologies for the treatment of sickle cell disease
Ramadier, S., Chalumeau, A., Félix, T., Othman, N., Aknoun, S., Casini, A., Maule, G., Masson, C., Cian, A. D., Frati, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.019 · Cited by 20
Lipidomics reveals perturbations in the liver lipid profile of iron-overloaded mice
Ding, H., Zhang, Q., Yu, X., Chen, L., Wang, Z., & Feng, J. (2021) · Metallomics · doi:10.1093/mtomcs/mfab057 · Cited by 17
Singh, P. C., Ahmed, M., Nihonyanagi, S., Yamaguchi, S., & Tahara, T. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c08581 · Cited by 17
Genetic alterations in uterine fibroids – a new direction for pharmacological intervention?
Markowski, D. N., Holzmann, C., & Bullerdiek, J. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1075510 · Cited by 17
“HMGA2 seems to drive the proliferation of hematopoietic stem and progenitor cells in humans and mice [76,77].”
BackgroundMorianos, I., Siapati, E. K., Pongas, G., & Vassilopoulos, G. (2011) · Gene Therapy · doi:10.1038/gt.2011.98 · Cited by 17
Ikeda, K., Ogawa, K., & Takeishi, Y. (2012) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.58.91 · Cited by 17
Meng, F., Xu, Y. X. Z., Dan, Q., Wei, L., Deng, Y., Liu, J., He, M., Liu, W., Xia, Q., Zhou, F. H., et al. (2015) · Cancer Science · doi:10.1111/cas.12609 · Cited by 17
Gene Therapy Strategies: Can We Eradicate HIV?
van Lunzen, J., Fehse, B., & Hauber, J. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0073-9 · Cited by 22
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm
BARONCIANI, D., Casale, M., Franceschi, L. D., Graziadei, G., Longo, F., Origa, R., Rigano, P., Pinto, V. M., Marchetti, M., Gigante, A., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000555 · Cited by 16
Effective therapies for sickle cell disease: are we there yet?
Crossley, M., Christakopoulos, G. E., & Weiss, M. J. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.07.003 · Cited by 22
Correcting inborn errors of immunity: From viral mediated gene addition to gene editing
Castiello, M. C., Ferrari, S., & VILLA, A. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101731 · Cited by 17
Fischer, A., Ehrlich, A., Plotkin, Y., Ouyang, Y., Asulin, K., Konstantinos, I., Fan, C., Nahmias, Y., & Willner, I. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202311590 · Cited by 17
Self-citationMesenchymal stem cells in craniofacial reconstruction: a comprehensive review
Zheng, Z., Liu, H., Liu, S., Luo, E., & Liu, X. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1362338 · Cited by 21
Retroviral integration profiles: their determinants and implications for gene therapy
Lim, K. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.4.207 · Cited by 17
“of various human diseases, including blood disorders, diabetes, and neurological disorders (2, 10-15).”
BackgroundPluripotent stem cell based gene therapy for hematological diseases
Vanhee, S., & Vandekerckhove, B. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.022 · Cited by 17
Nasimuzzaman, M., Kim, Y., Wang, Y., & Persons, D. A. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.20 · Cited by 16
Treating hemoglobinopathies using gene-correction approaches: promises and challenges
Cottle, R. N., Lee, C. M., & Bao, G. (2016) · Human Genetics · doi:10.1007/s00439-016-1696-0 · Cited by 20
“4c) (Jinek et al. Table 1 Summary of gene therapy studies using viral vectors Disease Vector Species Results/drawbacks References β-Thalassemia Lentiviral vector containing wild-type human HBB Mice Hemoglobin levels depends on vector copy number High copy number in bone marrow cells results in 32 % total hemoglobin co…”
BackgroundInfluentialLewis, G., Christiansen, L., McKenzie, J., Luo, M., Pasackow, E., Smurnyy, Y. D., Harrington, S., Gregory, P. D., Veres, G., Nègre, O., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.001 · Cited by 18
“VCN was assessed relative to an internal reference clone, Clone K3 cDNA, known to contain two copies of integrated viral DNA per diploid genome.(3)”
MethodGenetic Strategies for HIV Treatment and Prevention
Falkenhagen, A., & Joshi, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.018 · Cited by 17
“In one patient, monoclonal expansion of a gene-modified cell was observed, but the expansion was transient and was not associated with any malignancy.(165) In all other trials, polyclonal development of gene-modified HSPCs and their progeny was observed.”
ResultStavrou, E. F., Simantirakis, E., Verras, M., Barbas, C. F., Vassilopoulos, G., Peterson, K. R., & Athanassiadou, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-56056-z · Cited by 16
Uchida, N., Ferrara, F., Drysdale, C. M., Yapundich, M., Gamer, J., Nassehi, T., DiNicola, J., Shibata, Y., Wielgosz, M. M., Kim, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0411 · Cited by 17
The EHA Research Roadmap: Hematopoietic Stem Cell Gene Therapy
Naldini, L., Cicalese, M. P., Bernardo, M. E., Gentner, B., Gabaldo, M., Ferrari, G., & Aiuti, A. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000671 · Cited by 16
Targeting fetal hemoglobin expression to treat β hemoglobinopathies
Steinberg, M. H. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066519 · Cited by 19
“The first efficacious gene therapy used a lentiviral vector to introduce a modified HbA gene with the gln(87) residue of γglobin into CD34 HPSCs cells of a patient with HbE-β thalassemia [83].”
MethodHematopoietic Stem Cell Transplantation for Thalassemia
Elborai, Y. E. S., Uwumugambi, A., & Lehmann, L. (2012) · Immunotherapy · doi:10.2217/imt.12.95 · Cited by 16
Giordano, F. A., Sorg, U. R., Appelt, J.-U., Lachmann, N., Bleier, S., Roeder, I., Kleff, V., Flaßhove, M., Zeller, W. J., Allgayer, H., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.088 · Cited by 16
“…LMO 2, CCND 2, etc.) described in transformed and expanded cell clones in the past (Li et al. , 2002; Hacein-Bey-Abina et al. , 2003; Calmels et al. , 2005; Ott et al. , 2006; Cattoglio et al. , 2007; Deichmann et al. , 2007; Howe et al. , 2008; Cavazzana-Calvo et al. , 2010; Stein et al. , 2010).”
Moiani, A., Miccio, A., Rizzi, E., Severgnini, M., Pellin, D., Suerth, J. D., Baum, C., Bellis, G. D., & Mavilio, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055721 · Cited by 18
“On the other hand, the lower propensity to integrate within transcribed regions may reduce the recently emerged post-transcriptional component of insertional gene deregulation [23,36,37,38,39,40].”
BackgroundGene therapy for metabolic disorders: an overview with a focus on urea cycle disorders
Alexander, I. E., Kok, C., Dane, A. P., & Cunningham, S. C. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9467-0 · Cited by 17
Tarantal, A. F., & Skarlatos, S. I. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.178 · Cited by 16
“Significant advances have been made toward the successful treatment of inherited diseases by gene transfer (Brantly et al., 2009; Cartier et al., 2009; Cavazzana-Calvo et al., 2010; Ferrua et al., 2010; Hacein-Bey-Abina et al., 2010; Kohn, 2010; Perumbeti and Malik, 2010; Byrne et al., 2011; Grez et al., 2011; Bennett…”
Gene therapy for hemoglobin disorders - a mini-review
Malik, P. (2016) · Journal of Rare Diseases Research & Treatment · doi:10.29245/2572-9411/2016/2.1028 · Cited by 21
del Pozo‐Rodríguez, A., Rodríguez‐Gascón, A., Rodríguez-Castejón, J., Vicente-Pascual, M., Gómez-Aguado, I., Battaglia, L., & Solinís, M. Á. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_109 · Cited by 28
5′RNA Trans-Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa
Mayr, E., Ablinger, M., Lettner, T., Murauer, E. M., Guttmann‐Gruber, C., Hofbauer, J. P., Hainzl, S., Kaiser, M., Klausegger, A., Bauer, J. W., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031732 · Cited by 16
Cellular therapy for sickle cell disease
Abraham, A., Jacobsohn, D. A., & Bollard, C. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.011 · Cited by 20
“However, gene transfer approaches require fine-tuning to consistently offer high efficiency transduction and expression of the transgene without disturbing normal gene function or leading to a clonal expansion event [57, 60, 61].”
BackgroundMethodUchida, N., Demirci, S., Haro‐Mora, J. J., Fujita, A., Raines, L. N., Hsieh, M. M., & Tisdale, J. F. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.007 · Cited by 17
“Indeed, transfer of a therapeutic adult Hb has recently been shown of benefit for SCD patients participating in ongoing gene therapy trials.(1,2) The serum-free differentiation media decreased fetal Hb production as compared to serum-containing differentiation media (Figure 4), which should allow for more clear separa…”
BackgroundInfluentialGene therapies advance towards finish line
Mullard, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3572 · Cited by 16
Combinatorial suicide gene strategies for the safety of cell therapies
Falcon, C., Smith, L. C., Al‐Obaidi, M., Zaanona, M. I. A., Purvis, K., Minagawa, K., Athar, M., Salzman, D. E., Bhatia, R., Goldman, F. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975233 · Cited by 16
“Gene-modified HSC infused into patients with monogenic disease (6, 7, 9, 10, 14), resulted in leukemia from insertional mutagenesis in several patients.”
BackgroundThe effect of red blood cell disorders on male fertility and reproductive health
Naelitz, B. D., Khooblall, P., Parekh, N. V., Vij, S. C., Rotz, S. J., & Lundy, S. D. (2024) · Nature Reviews Urology · doi:10.1038/s41585-023-00838-8 · Cited by 16
“This novel gene therapy treatment consists of functional β-globulin gene transduction into patient-derived haematopoietic stem cells before autologous transplantation, and was shown to achieve sustained transfusion independence in >85% of patients 85,86 .”
Lemmens, M., Dorsheimer, L., Zeller, A., & Dietz, Y. (2024) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2024.503767 · Cited by 16
Gene Therapy: A Revolutionary Step in Treating Thalassemia
Salama, R. A. A., Qureshi, G. S. A., Safdar, M., Raafat, A., Janardhan, G., Elshamy, H. A. H., & Jhancy, M. (2024) · Hematology Reports · doi:10.3390/hematolrep16040064 · Cited by 15
Sjeklocha, L. M., Wong, P. Y.-P., Belcher, J. D., Vercellotti, G. M., & Steer, C. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080403 · Cited by 15
“In addition the modified β-globin derivative βT87Q, which has anti-sickling properties, has been used in an ongoing human trial for βthalassemia as well as in this study to maximize potential benefits of an SB delivered IHK transgene [12,27].”
MethodMyocardial Repair and Regeneration: Bone Marrow or Cardiac Stem Cells?
Oldroyd, K. G., Berry, C., & Bartúnek, J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.99 · Cited by 15
Gene therapy: therapeutic applications and relevance to pathology
Both, G. W., Alexander, I. E., Fletcher, S., Nicolson, T. J., Rasko, J. E. J., Wilton, S. D., & Symonds, G. P. (2011) · Pathology · doi:10.1097/pat.0b013e32834b1dad · Cited by 17
“On a cautionary note, the therapeutic benefit appeared to, at least in part, arise from a clonally expanded progenitor population with a vector integration event in the HMG2A gene.(26) Collectively, these early results in each of the three major blood lineages unequivocally demonstrate the therapeutic potential of gen…”
BackgroundCurative approaches for sickle cell disease: A review of allogeneic and autologous strategies
Bauer, D. E., Brendel, C., & Fitzhugh, C. D. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.014 · Cited by 15
Gene Therapy: A New Approach in Modern Medicine
Yazdani, A., Alirezaie, Z., Motamedi, M. J., & Amani, J. (2018) · International Journal of Medical Reviews · doi:10.29252/ijmr-050304 · Cited by 20
Leggiero, E., Labruna, G., Iaffaldano, L., Lombardo, B., Greco, A., Fiorenza, D., Gramanzini, M., Montanaro, D., Baldi, A., Cerullo, V., et al. (2019) · Gene Therapy · doi:10.1038/s41434-019-0061-z · Cited by 15
Current and future gene therapies for hemoglobinopathies
Brendel, C., & Williams, D. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000581 · Cited by 15
“The first successful gene therapy for a b-hemoglobinopathy was reported a decade ago and transfusion independence has been achieved for one ß/ ß-thalassemia patient [12].”
Background
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.